EGFR and non-small cell lung carcinoma: The phase III trial HERTHENA-Lung02 is currently underway, evaluating patients with advanced NSCLC refractory to third-generation EGFR-TKIs, and also permits patients with stable BM to participate in the study (Table 2) [108].